Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 41.97M shares rose 1.8% year over year, behind the +3.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.8% toward the trailing-twelve-month pace of +3.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.97M-1.1% QoQ
Last fiscal yearDec 2025
42.42M+3.9% YoY
LTMMar 2026
42.44M+3.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.8%——
1 year+3.9%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
42.42M USD
Year-over-year change
+3.9%
4-year CAGR
+10.5%

Weighted Avg Shares (Diluted) vs competitors

How ORMP compares with its peers on the latest reported figures

  • ORMP's LTM Mar 2026 weighted avg shares (diluted) of 42.44M shares is the 7th highest of the 11 companies compared; the peer median is 59.46M shares.
  • Its year-over-year change of +3.8% is the 8th highest of 11, against a peer median of +10.3%.
  • Over three fiscal years its annual growth of +2.8% compares with a peer median of +16.5%.
ORMP Competitors Peer median
Weighted Avg Shares (Diluted) for ORMP and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
Peer median (excluding ORMP) 59.46M+10.3%+16.5%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.7M2.7M1.34M02M
Cost of Revenue000193K1.99M
Gross Profit2.7M2.7M1.34M(193K)13K
Gross Margin100.0%100.0%100.0%—0.7%
Research & Development20.99M27.64M8.97M6.32M6.38M
Selling, General & Admin5.94M15.66M8.14M6.46M8.72M
Operating Expenses26.93M43.3M17.11M12.78M15.1M
Depreciation & Amortization77K3.62M196K193K121K
EBITDA(25.04M)(36.98M)7.32M(14.87M)75.45M
EBITDA Margin-926.3%-1368.0%546.3%—3772.2%
Operating Income(24.22M)(40.6M)(15.77M)(12.78M)(15.09M)
Operating Margin-896.2%-1502.0%-1176.8%—-754.4%
Interest Income347K3.57M8.03M02.37M
Interest Expense6K03.58M853K0
Other Income / Expenses893K2.93M20.86M(3.14M)90.41M
Income Before Tax(22.99M)(37.66M)5.09M(15.92M)75.32M
Pre-Tax Margin-850.5%-1393.4%379.7%—3766.2%
Income Tax Expense(2.88M)100K03.18M11.31M
Net Income(22.24M)(37.76M)5.53M(19.1M)64.05M
Net Margin-822.7%-1397.1%412.3%—3202.5%
EPS (Basic)(0.78)(0.97)0.14(0.47)1.53
EPS (Diluted)(0.78)(0.97)0.14(0.47)1.50
Weighted Avg Shares28.47M39M40.32M40.83M41.4M
Weighted Avg Shares (Diluted)28.47M39M40.57M40.83M42.42M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.